ABIOGEN PHARMA: THE ITALIAN EXCELLENCE FROM FIVE GENERATIONS

Abiogen Pharma is one of the top 30 pharmaceutical companies in Italy, with over 350 employees and a turnover of about 160 milion € in 2016.

We focus our activities on some therapeutic areas such as: osteoarticular pathologies, pain management, dermatology, pediatric respiratory and diabetes.

In a scenario dominated by the processes of international concentration and integration, a Company strategy geared to change and flexibility is the most valid key to avoid a subordinate role to the globalizing policy of multinational groups. 


Innovation is also the key to flexibility and the pivot on which the Manufacturing activity operates at the state of the art production site opened in Pisa in 2001.


Moreover, Abiogen international expansion is one of the drivers that will support the company’s growth during the next years. Recent partnerships and alliances will allow Abiogen to export more and more “made in Italy” abroad.


Abiogen Pharma applied to the Italian successful model a flexible and innovative approach with a strong vocation for internationalization.


On the other hand It have pursued a strategy to make therapeutic solutions widely accessible, so that all the people can benefit from it.

Go to article: Home | A New Class of TreatmentGo to article: EditorialGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: DistekGo to article: The pharma industry briefingGo to article: DelSiTechGo to article: Big soil: A $1bn project to develop new drugs from earthGo to article: Novo NordiskGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: medical hempGo to article: Cannabinoids breakthrough signals hope for epilepsy treatment Go to article: CBDepot Company InsightGo to article: CBDepotGo to article: Capsugel Company InsightGo to article: Could cutting out mediators let cancer research off the leash? Go to article: EcocoolGo to article: The next generation of antimalarials Go to article: AlpexGo to article:  Pharma air freight: what does it take to get certified? Go to article: PangeanicGo to article: Blocking generic competition: will naming and shaming work?Go to article: Haselmeier GmbH Company InsightGo to article: Haselmeier GmbH Go to article: EventsGo to article: Abiogen PharmaGo to article: Next issueGo to article: HOF SonderanlagenbauGo to article: EvolveGo to article: ILC Dover Inc